• 1
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 2
    McHutchinson JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006; 44: 411421.
  • 3
    McHutchinson JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, et al. A phase 1B, randomized, double-blind, does escalation trial of CPG 10101 in patients with chronic hepatitis C virus. HEPATOLOGY 2007; 46. DOI 10.1002/hep.21773.
  • 4
    Development discontinued for ANA975, an early stage compound for treatment of hepatitis C virus infection [press release]. San Diego, CA: Anadys Pharmaceuticals Inc.; July 26, 2007. Available at: Accessed September 24, 2007.
  • 5
    Valopicitabine development program placed on clinical hold in the United States [press release]. Cambridge, MA: Idenix Pharmaceuticals Inc.; July 13, 2007. Available at: Accessed September 24, 2007.
  • 6
    Potential safety issue identified in ongoing phase 2 clinical study of HCV-796 [press release]. Exton, PA: ViroPharma Inc.; August 10, 2007. Available at: Accessed September 24, 2007.
  • 7
    U.S. Food and Drug Administration. Summary Minutes of the Antiviral Drug Advisory Committee Meeting, October 19-20, 2006. Available at: Accessed September 24, 2007.
  • 8
    Northrup J. The pharmaceutical sector. In: Lawton RB, ed. The Business of Healthcare Innovation. Cambridge, UK: Cambridge University Press; 2005: 27102.
  • 9
    Chemmanur AT, Wu GY. Drug evaluation: Albuferon-alpha – An antiviral interferon-alpha/albumin fusion protein. Curr Opin Investig Drugs 2006; 7: 750758.